The company said reported net sales for Q2 2025 were $2.76 billion, down 4% from the prior-year period, and that currency neutral sales on a comparable basis, excluding divestitures, rose 3%.

1. 01

   The company said reported net sales for Q2 2025 were $2.76 billion, down 4% from the prior-year period, and that currency neutral sales on a comparable basis, excluding divestitures, rose 3%.

2. 02

   The company said adjusted operating EBITDA for Q2 was $552 million, with a margin of 20.0%, and that on a comparable currency neutral basis it improved 6% from the prior-year period. The company cited volume growth, net pricing and productivity as the factors.

3. 03

   The company said its Board authorized a share repurchase program of up to $500 million on August 5, 2025 (the 2025 Program) with no specified term. It plans to fund repurchases from available cash and cash provided by operating activities. Net debt to credit adjusted EBITDA was 2.5x at the end of Q2.

4. 04

   The company said it entered into a definitive agreement to sell its soy crush, concentrates and lecithin business to Bunge and expects the transaction to close by year-end 2025. The business generated approximately $240 million in revenue in 2024. Financial terms of the deal were not disclosed.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.